Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Inventory (2023 - 2025)

Iovance Biotherapeutics has reported Inventory over the past 3 years, most recently at $51.7 million for Q4 2025.

  • Quarterly results put Inventory at $51.7 million for Q4 2025, changed 0.31% from a year ago — trailing twelve months through Dec 2025 was $51.7 million (changed 0.31% YoY), and the annual figure for FY2025 was $51.7 million, changed 0.31%.
  • Inventory for Q4 2025 was $51.7 million at Iovance Biotherapeutics, roughly flat from $51.7 million in the prior quarter.
  • Over the last five years, Inventory for IOVA hit a ceiling of $65.5 million in Q1 2025 and a floor of $9.2 million in Q3 2023.
  • Median Inventory over the past 3 years was $49.8 million (2025), compared with a mean of $35.2 million.
  • Biggest five-year swings in Inventory: skyrocketed 396.72% in 2024 and later increased 0.31% in 2025.
  • Iovance Biotherapeutics' Inventory stood at $10.4 million in 2023, then surged by 396.72% to $51.5 million in 2024, then grew by 0.31% to $51.7 million in 2025.
  • The last three reported values for Inventory were $51.7 million (Q4 2025), $51.7 million (Q3 2025), and $49.8 million (Q2 2025) per Business Quant data.